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Abstract
Background: Multiple endocrine neoplasia (MEN1) is a rare inherited multi-tumour syndrome, affecting specific
neuroendocrine organs and non-endocrine tissues with a variable spectrum of over 20 possible different
combinations, caused by inactivating heterozygote mutations of the MEN1 gene.
Disease onset, penetrance, clinical presentation, course and prognosis are all extremely variable, even among
individuals bearing the same causative mutation, which doesn’t allow prediction of the individual clinical
phenotype (based on the specific result of the genetic test), thus compelling all patients and mutation carriers to
undergo a common routine general screening program.
Results: We performed an extensive epidemiological, clinical and genetic analysis of the Florentine MEN1 patient
database, which includes 145 MEN1 patients and 20 asymptomatic MEN1 carriers, constantly followed up at the
Regional Referral Centre for Inherited Endocrine Tumours of the Tuscany Region, during the last three decades. We
reported, here, the results of clinical, epidemiological and genetic descriptive statistics, as well as correlation
analyses between tumours and mutation types and localisation. No direct genotype-phenotype correlation was
described, but the importance of the genetic testing was confirmed for an early diagnosis and the identification of
asymptomatic carriers.
Conclusions: As with all rare diseases, the possibility to collect and analyse data on a relatively large number of
patients is important for increasing our knowledge of the epidemiologic aspects of the disease, and its natural
course and prognosis of single manifestations of the syndrome, in order to set up the best diagnostic and
therapeutic plans for patients. In this light, the creation and constant updating of large patient databases is
fundamental. Results from database study can provide useful epidemiological, clinical and genetic information
about MEN1 syndrome, which could help clinicians in the diagnostic and therapeutic management of single MEN1
patients.
Keywords: Multiple endocrine neoplasia type 1 (MEN1), MEN1 gene, Genetic test, Primary hyperparathyroidism
(PHPT), Gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs), Pituitary adenomas, Patients’ database
Background
Multiple endocrine neoplasia (MEN1) is a rare (preva-
lence 3–20/100,000) congenital endocrine syndrome,
consisting of the development of multiple neuroendo-
crine tumours (NETs) in a single patient, principally at
parathyroid glands, anterior pituitary and gastro-entero-
pancreatic (GEP) and thoracic tracts. Other endocrine
and non-endocrine tissues can be affected with less fre-
quency, accounting for over 20 different combinations of
tumours and lesions.
Principally affected organs are the parathyroids; para-
thyroid multiple adenomas affect up to 100% of patients
by the age of 50, representing the first clinical manifest-
ation in about 90% of cases with a mean age of onset of
20–25 years and rare described cases also by the age of
8 [1]. Parathyroid disease manifests principally as
primary hyperparathyroidism (PHPT), which can be
normocalcemic in some cases, and often remains
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asymptomatic in many patients. Symptomatic PHPT is
due to the prolonged hypercalcemia and it usually re-
sults in loss of bone mass (osteopenia or osteoporosis)
and/or nephrocalcinosis. Adenoma ablation by surgery is
the treatment of choice, mostly for hypercalcemic and
symptomatic cases, even if both the right time and the
kind of intervention are still controversial. Pharmaco-
logical treatment with calcimimetic drugs demonstrated
to be able to control hypercalcemia in patients who do
not meet the criteria for parathyroid surgery or do not
want to undergo the intervention [2].
The second most common manifestation in MEN1 are
neuroendocrine tumours of the GEP tract (GEP-NETs),
affecting about 30–70% of patients [1], usually manifest-
ing as multiple adenomas and often recurrent after sur-
gical resection. They present both as micro- or
macro-adenomas (diameter over 0.5 cm), and can be
non-functioning tumours (NFTs; 20% of GEP-NETs) or
active tumours secreting excessive quantities of hor-
mones. NFTs are located mainly in the pancreas and
usually they remain asymptomatic till their excessive
growth causes compression of adjacent tissues and/or
their (frequent) malignant progression and metastases
manifest. A continuous imaging surveillance is required
and surgery ablation is suggested for NFTs over 0.5 cm
in diameter. Recently, also non-functioning NETs
(NF-NETs) of the stomach (previously referred as gastric
carcinoid of type II enterochromaffin-like cells) have
been included in the GEP-NETs group; they have an es-
timated penetrance of about 10% of MEN1 patients.
Functioning GEP-NETs produce excessive hormones,
such as gastrin, insulin, somatostatin, glucagon or vaso-
active intestinal polypeptide (VIP), causing in many
cases an associated endocrine syndrome, and they are,
respectively, named gastrinomas, insulinomas, somatos-
tatinomas, glucagonomas and VIPomas. Gastrinomas
are the most common (over 50% of cases) MEN1 secret-
ing GEP-NETs; about 90% are located in the duodenum
and 10% in the pancreas. Pancreatic gastrinomas are
more aggressive. Over secretion of gastrin is responsible
for Zollister Ellison Syndrome (ZES) in many cases. Usu-
ally, MEN1 gastrinomas are small (less than 0.5 mm)
and multiple, with a frequent rate of malignant progres-
sion and metastases development, being, together with
severe ulcers, one of the most common causes of
MEN1-related premature deaths. Insulinomas are the
second most common GEP-NETs in MEN1, manifesting
in 10–30% of patients, often as multiple tumours. Sur-
gery is usually the therapeutic approach to GEP-NETs,
but it is not always effective due to multiple nature of
these tumours that are often scattered through the entire
neuroendocrine tissue. In case of non-resectable tu-
mours or advanced metastatic cancer, some pharmaco-
logical treatments demonstrated to be effective in
increasing median progression-free survival [i.e somato-
statin analogues (SSAs), cytotoxic chemotherapy (strep-
tozocin and 5-fluorouracil, doxorubicin, temozolomide
with capecitabine), inhibitors of thyrosin kinase recep-
tors (sunitinib), and inhibitors of the mammalian target
of rapamycin (everolimus)].
Adenomas of anterior pituitary gland affect about 30–
40% of MEN1 patients and represent the third most com-
mon tumours in MEN1. They can be hormone-secreting
or NFTs. Often they develop as single tumours, are
non-invasive, and very rarely manifest a malignant pro-
gression. Signs and symptoms are principally due to
macro-adenomas compressing cerebral structures, or spe-
cifically derived by the over-production of one or more pi-
tuitary hormones (i.e prolactin, PRL; somatotropin, GH;
and corticotropin, ACTH). Functioning tumours are
prolactinomas (PRLomas, 60% of pituitary adenomas),
somatotropinomas (25%) or corticotropinomas (5%).
Trans-sphenoidal or endoscopic resection or radioablation
are the treatments of choice for macro-adenomas and
NFTs. PRL-secreting micro-adenomas are pharmacologic-
ally treated by dopamine agonists, while somatotropino-
mas are treated with SSAs.
Other MEN1-associated NETs are thoracic carcinoids,
of the thymus and the bronchopulmonary tract, in 3% of
cases, and tumours/lesions of the adrenal glands in
about 20–40% of patients.
Non-endocrine multiple skin lesions are also frequent
(i.e collagenomas, angiofybromas, fibromas, angiomas,
and lipomas), often manifesting even before of MEN1
neuroendocrine tumours and being, thus, useful in fa-
voring an early diagnosis. Lipomas can manifest also at
visceral level.
Germinal inactivating heterozygote mutations of the
MEN1 tumour suppressor gene have been identified as
responsible for the development of the syndrome, mostly
through the loss of the second wild type copy of the
gene at somatic level of specifically predisposed neuro-
endocrine tissues. To date, over 1500 different germinal
and somatic mutations, spanning the entire coding re-
gion (exons 2–10) and splicing sites of MEN1, have been
described, none of them being associated with a specific
clinical phenotype and/or disease penetrance [3, 4]. The
lack of a direct genotype-phenotype correlation does not
allow to foresee the exact clinical course and tumour
localization of the disease, to program personalised diag-
nostic screening or therapeutic plans.
Here we performed an extensive epidemiological,
clinical and genetic analysis of the wide Florentine
MEN1 patients’ database, which includes MEN1 pa-
tients and asymptomatic MEN1 carriers constantly
followed up at the Regional Referral Centre for Inher-
ited Endocrine Tumours of the Tuscany Region, dur-
ing the last three decades.
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Materials and methods
Patients
Patients included in this study have been clinically fol-
lowing up at the Ambulatory of the Regional Referral
Centre for Inherited Endocrine Tumours of the Tuscany
Region, at the “Azienda Ospedaliero-Universitaria Car-
eggi, Firenze” from 1991 to date. The clinical and genetic
study was approved by the Internal Review Board of the
“Azienda Ospedaliero-Universitaria Careggi, Firenze”.
All patients enrolled in the study, or their legal tutors in
case of patients less than 18 years, were requested to
sign an informed consent form prior their data were in-
cluded in the analysis. Collected data were appropriately
made anonymous and each patient was identified by a
unique alphanumeric identification code; data were all
analysed as aggregates.
We included in this study a total of 165 MEN1 pa-
tients [59 males (35.8%) and 106 females (64.2%)], of
which 27 are referred as simple cases and 138 as familiar
cases (from 51 different pedigrees). Familial cases were
defined when at least two MEN1 clinical cases are iden-
tified within a family or when at least two family mem-
bers bear a MEN1 mutation.
We collected, in a specific computed database, data
about gender, date of birth, familial and personal clinical
history (i.e. age at clinical and genetic diagnosis, type
and age of onset of the first clinical manifestation, all
endocrine and non-endocrine MEN1-associated mani-
festations and related signs and symptoms, past and
present MEN1 therapies, all surgical MEN1 interven-
tions) and the result of the MEN1 genetic test.
According to International guidelines, the MEN1 diag-
nosis was established based on one of these three cri-
teria: 1) presence of tumours in at least two of the three
main organs/tissues affected in MEN1, 2) presence of tu-
mours in one of the three main organs/tissues affected
in MEN1 and a first-degree relative affected by MEN1,
3) the identification of a germinal inactivating mutation
of the MEN1 gene.
Age at diagnosis was considered the age at which the
syndrome was definitely recognised; for each patient we
considered an age at clinical diagnosis (recognition of
MEN1 by clinical signs and/or symptoms) and an age at
genetic diagnosis (age of genetic identification of a
MEN1 mutation).
PHPT was classified as symptomatic only when pa-
tients manifested secondary signs and/or symptoms due
to prolonged hypercalcemia, such as nephrolithiasis and/
or secondary osteopenia and osteoporosis; patients with
elevated parathyroid hormone (PTH), with or without
hypercalcemia, but without any associated secondary
clinical signs were considered asymptomatic PHPT.
GEP-NETs were classified as non-functioning if they did
not secrete hormones or secreted only neuroendocrine
polypeptides which do not cause a specific clinical
syndrome [i.e chromogranin A and pancreatic poly-
peptide (PP)].
Patients not showing any clinical sign and/or symptom
associated with MEN1 at the time of this study were
considered as asymptomatic and they were excluded
from the analysis of genotype-phenotype association.
MEN1 genetic analysis
MEN1 genetic screening for mutations was performed in
all the 165 patients of our database by PCR-based San-
ger’s sequencing of genomic DNA from blood. We ana-
lysed the coding region (exons 2–10) and the
splicing-sites of the gene; obtained sequences were com-
pared to the human wild type reference sequence of the
MEN1 gene (OMIM 613733); mutations were classified
using the standard nomenclature for human DNA se-
quence variants. When a mutation was identified in a
MEN1 index case, the genetic analysis for this specific
mutation was extended also to first degree relatives.
Among the 16 MEN1 patients resulted negative by San-
ger’s sequencing, 6 patients (from 3 different families)
were further investigated. One family was analysed by
microsatellite-based haplotype linkage analysis at 11q13
locus. The other two families were screened (by two ex-
ternal laboratories) by multiplex ligation-dependent
probe amplification (MPLA) to identify large intragenic
deletions/insertions.
Statistical analyses
Clinical manifestations, age at diagnosis, therapies (sur-
gical and pharmacological), mutation distribution and
classification were all analysed by descriptive statistics;
data are presented as nominal categories, percentages or
mean + standard deviation (SD).
Correlations between clinical data and mutation type
and/or mutated gene region were analysed by
chi-squared test, assuming a positive significance with p
< 0.05 (Yates’ correction was applied for subgroups con-
taining less than 5 cases). Only the four main mutation
types (frameshift, nonsense, missense and splicing site)
and only mutations at exons 2, 3, 9, 10 and intron 4
were included in the comparative analyses, since double
mutation, large intragenic deletions, predisposing haplo-
type, absence of an identified mutation, and mutations
located in all the other exons/introns were all carried by
a very little number of patients (< 10) to be able to carry
on a sufficiently strong association statistical test.
Results
Patients
Of the 165 MEN1 patients included in the database, 145
were clinically affected at the time of this study, while 20
showed no signs of the disease (asymptomatic mutation
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carriers). PHPT, GEP-NETs and pituitary tumours re-
sulted to be the three most common clinical manifesta-
tions in affected subjects, respectively in 139 (95.86%),
86 (59.31%) and 75 (51.72%) cases. Detailed prevalence
of MEN1 tumours/lesions in our series is reported in
Table 1, in comparison to data reported in the latest
MEN1 guidelines [1].
Forty-six of the affected patients (31.72%) presented
one of any clinical combination of the triad PHPT,
GEP-NETs and pituitary adenomas. Most common
phenotypical combinations were, in order of frequency:
PHPT/GEP-NETs/pituitary tumours in 46 cases
(31.72%), PHPT/GEP-NETs in 36 cases (24.83%), PHPT/
pituitary tumours in 24 cases (16.55%) and GEP-NETs/
pituitary tumours in 3 cases (2.07%). Distributions of
clinical manifestations in our series of patients are
depicted in detail in Table 2.
Mean age of the first clinical manifestation was
31.8 + 13.5 years (range 9–71 years).
Mean age at diagnosis for index cases (both single and
familial) was 40.6 + 15.6 years (range 4–73 years). Age
at genetic diagnosis for relatives of the index cases was
31.2 + 16.9 years (range 1–71 years), with a positive
mean gap of about 10 years in anticipating diagnosis
with respect to probands. Twenty individuals identified
as mutation carriers resulted free of any MEN1 clinical
sign or symptom at the time of the study and were con-
sidered as asymptomatic; they are still under constant
MEN1 diagnostic surveillance, according to Inter-
national guidelines [1].
Nine patients died (6.21% of affected patients) because
of MEN1-related causes and malignant progression of
MEN1 tumours. Mean age of death was 63.9 + 14.6
(range 37–88 years). Three died for liver metastases
from gastrinoma, one for severe peptic ulcer, one for se-
vere gastric bleeding, one for atrial fibrillation and hypo-
kalemia, one for post-surgical hyponatremia for
recurrent PRLoma, one for post-surgical complications
of a recurrent lung carcinoid and one for a lung carcin-
oid and untreated ZES. Mean age of first clinical mani-
festation was 39.6 + 16.8 (range 17–63 years), mean age
at MEN1 diagnosis was 56.6 + 9.8 years (range 35–
71 years) with a gap between the first manifestation oc-
currence and the correct diagnosis of over 15 years.
PHPT
One hundred thirty-nine patients were affected by PHPT
(47 men and 92 women). Mean age at diagnosis of
PHPT was 34.3 + 13.1 years (range 7–73 years), while
mean age of MEN1 diagnosis, for these patients, was
35.1 + 15.3 years (range 7–73 years).
In 23 cases, PHPT was the only clinical manifestation
(15.86% of MEN1 symptomatic affected patients; 16.55%
of patients with PHPT), while in 116 cases PHPT was
associated with other MEN1 tumours/lesions, as re-
ported in Table 2.
PHPT was the first clinical manifestation in 92 cases
(63.45% of all MEN1 affected patients; 66.19% of PHPT
cases); 25 of them were diagnosed with PHPT after
symptoms of nephrocalcinosis and/or renal colic, while
67 were biochemically diagnosed in presence of elevated
serum PTH and, in the great majority of cases (65), also
hypercalcemia. Mean age of PHPT discovery, in these 92
patients, was 34.4 + 13.5 (range 12–71 years). Fifty-two
were index cases [mean age of PHPT discovery 33.0+
12.5 (range 14–66 years)] and 40 were relatives of a
MEN1 proband [mean age of PHPT discovery 36.2+
14.5 (range 12–71 years)].
Ninety-nine PHPT affected patients underwent para-
thyroid surgery (71.22% of PHPT affected patients),
while 40 did not undergo any parathyroid surgery (13 of
them were treated with cinacalcet). Total parathyroidec-
tomy (TPT) was the most performed surgical approach
in our patients (47 cases; 33.81% in all PHPT affected
patients and 47.47% of parathyroid surgical interven-
tions); parathyroid tissue autograft in the non-dominant
forearm was performed in 43/47 cases (91.49%). A per-
centage of both subtotal parathyroidectomy (SPT) and
partial parathyroidectomy (PPT) required a second
intervention for adenoma recurrences [2 cases for STP
(11.76%) and 14 cases for PPT (40%)]: 10 TPTs (only
one without tissue autograft), 2 SPTs and 4 PPTs. Five
cases of permanent post-surgical hypoparathyroidism
were reported (5.1% of all operated patients; 10.6% of
TPT), all of them after a TPT.
Principal characteristics and treatments of PHPT in
our series are reported in Table 3.
GEP-NETs
Eighty-six patients were affected by GEP-NETs (26 men
and 60 women). Mean age at diagnosis of GEP-NETs
was 40.1 + 13.1 (range 14–73 years), while mean age of
MEN1 diagnosis, for these patients, was 33.6 + 12.8
(range 14–63 years).
Only one patient presented a GEP-NET (pancreatic
NET; pNET) as the only clinical manifestation (0.69% of
MEN1 symptomatic affected patients; 1.16% of patients
with GEP-NETs); in all the other 85 cases GEP-NETs
were associated with other MEN1 tumours/lesions, as
reported in Table 2.
A GEP-NET was the first clinical manifestation in 20
individuals (13.79% of all MEN1 affected patients;
23.26% of GEP-NET cases); 9 of them were gastrinomas
(of which 4 were diagnosed after manifesting ZES, 2
after presenting duodenal ulcer and 3 after gastric symp-
toms), 8 were insulinomas (of which 4 were diagnosed
after manifesting constant hypoglycaemia and/or recur-
rent hypoglycaemic crisis), one was VIPoma (initially
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Table 1 Prevalence of MEN1 tumours/lesions in our series with respect to published data*
Prevalence in
our patients
n. (%)
Type and combination of tumours/lesions in our patients
n. (%)
Prevalence in published
literature
(%)
PHPT 139 (95.86%) 139 PHPT: 90%
- 85 asymptomatic cases (61.15%)
- 36 with nephrocalcinosis (25.90%)
- 7 with osteoporosis (5.03%)
- 7 with nephrocalcinosis and osteoporosis (5.03%)
- 2 with osteopenia (1.44%)
- 2 with nephrocalcinosis and osteopenia (1.44%)
GEP-NETs 86 (59.31%) 30–70%
100 total tumours:
- 41 gastrinomas (28.27% of MEN1 affected patients; 41% of GEP-NETs) 40%
- 16 insulinomas (11.03% of MEN1 affected patients; 16% of GEP-NETs) 10%
- 39 pNFTs (including 1 PPoma) (26.90% of MEN1 affected patients;
39% of GEP-NETs)
20–55%
- 2 VIPomas (1.38% of MEN1 affected patients; 2% of GEP-NETs) < 1%
- 1 glucagonoma (0.69% of MEN1 affected patients; 1% of GEP-NETs) < 1%
- 1 gastric NF-NET (0.69% of MEN1 affected patients; 1% of GEP-NETs) 10%
Combinations:
- 28 gastrinoma alone (32.56% of patients affected by GEP-NETs)
- 13 insulinoma alone (15.12% of patients affected by GEP-NETs)
- 29 pNFTs alone (including 1 PPoma) (33.72% of patients affected
by GEP-NETs)
- 2 VIPoma alone (2.33% of patients affected by GEP-NETs)
- 9 gastrinoma-pNFTs (10.47% of patients affected by GEP-NETs)
- 3 gastrinoma-insulinoma (3.49% of patients affected by GEP-NETs)
- 1 gastrinoma-glucagonoma (1.16% of patients affected by GEP-NETs)
- 1 pNFT-gastric NF-NET (1.16% of patients affected by GEP-NETs)
Pituitary tumours 75 (51.72%) 30–40%
76 total tumours:
- 60 PRLomas (41.38% of MEN1 affected patients; 78.95% of pituitary
tumours)
20%
- 12 NFA (8.28% of MEN1 affected patients; 15.79% of pituitary tumours) < 5
- 3 ACTH-secreting tumours (corticotropinomas) (2.07% of MEN1 affected
patients; 3.95% of pituitary tumours)
< 5%
- 1 GH-secreting tumour (somatotropinoma) (0.69% of MEN1 affected
patients; 1.32% of pituitary tumours)
10%
Combinations:
- Only one combination of PRLoma-somatotropinoma (1.33% of
patients affected by pituitary adenoma)
Carcinoids 17 (11.72%) 17 bronchopulmonary (11.72% of MEN1 affected patients) Bronchopulmonary NETs 2%
Thymic NETs 2%
Skin lesions 44 (30.34%) 53 total skin lesions: 30%
- 37 lipomas: 17 single lipomas and 20 multiple lipomatosis (25.52%
of MEN1 affected patients; 69.81% of skin lesions)
85%
- 9 angiofibromas (6.21% of MEN1 affected patients; 16.98% of skin lesions) n.a
- 4 angiomas (2.76% of MEN1 affected patients; 7.55% of skin lesions) n.a
- 3 fibromas (2.07% of MEN1 affected patients; 5.66% of skin lesions)
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diagnosed by elevated serum VIP level), one was PPoma
(initially diagnosed by elevated serum PP and chromo-
granin A levels) and one was a gastric NF-NET. Mean
age of first GEP-NET biochemical or imaging discovery,
in these 20 patients, was 30.9 + 12.2 (range 14–59 years).
Fourteen were index cases [mean age of GEP-NET dis-
covery 33.5+ 12.7 (range 14–59 years)] and 6 relatives of
a MEN1 proband [mean age of GEP-NET discovery 23.6
+ 6.2 (range 17–35 years)].
Forty-five patients with GEP-NETs underwent pan-
creas/duodenal surgery (52.33%% of GEP-NET affected
patients). Partial pancreas resection or selective tumour
enucleation were performed in 28 of all the
GEP-NET-operated patients (32.56% of GEP-NET af-
fected patients and 62.22% of GEP-NET interventions),
while 17 patients underwent Whipple’s procedure
(19.77% of GEP-NET affected patients and 37.78% of
GEP-NET interventions). One patient was treated with
SSAs-conjugated radionuclide therapy with (177)Lu-DO-
TATATE for non-resectable pNET, while another patient
was firstly treated with SSAs, followed by four cycle of
SSAs-conjugated radionuclide therapy with (177)Lu-DO-
TATATE before undergoing pancreaticoduodenectomy
with partial liver resection.
Principal characteristics and treatments of GEP-NETs
in our series are reported in Table 4.
Pituitary tumours
Seventy-five patients manifested at least one pituitary tu-
mours (21 men and 54 women).
Mean age at diagnosis of pituitary tumours was 33.0 + 14.3
(range 7–69 years), while mean age of MEN1 diagnosis, for
these patients, was 31.5 + 14.0 (range 7–57 years).
Two individuals (both index cases and non-familial
cases), aged respectively 48 and 55 years at the time of this
study, presented only a PRLoma as MEN1 manifestation
(diagnosed at the age of 36 and 50 years, respectively). In
all the other 73 cases, pituitary tumours were associated
with other MEN1 tumours/lesions, as reported in Table 2.
PRLoma was the most common pituitary tumour
(80%), affecting 60 individuals (one in association with
somatotropinoma). A detailed distribution of pituitary
tumours in our patients is depicted in Table 1.
A pituitary tumour was the first clinical manifestation
in 25 patients: 24 were PRLomas (all of them were diag-
nosed by biochemical recognition of high serum level of
PRL; 4 presented signs of amenorrhea, 1 of oligomenor-
rhea, 2 of galactorrhea, 1 of both oligomenorrhea and
galactorrhea and 1 woman presented hypogonadism and
androgenic phenotypical manifestations) and one corti-
cotropinoma. Mean age of pituitary tumour discovery, in
these 25 patients, was 26.7 + 12.3 (range 12–55 years).
Eighteen were index cases [mean age of pituitary tumour
discovery 30.6+ 12.6 (range 12–55 years)] and 7 relatives
of a MEN1 proband [mean age of pituitary tumour dis-
covery 18.1+ 5.8 (range 12–30 years)].
Over-production of PRL was controlled by pharmaco-
logical therapy with dopamine agonist (cabergoline) in
30 patients affected by PRLoma (50% of patients affected
by PRLomas). One patient had to stop cabergoline
therapy because she manifested hypotension and head-
ache. Transphenoidal resection of pituitary adenomas
was performed in 11 patients (14.67% of pituitary
tumour-affected patients): 2 were ACTH-secreting
tumours, 1 was a GH-secreting tumour, 2 were
non-secreting adenomas and 6 were macro-PRLomas
Table 1 Prevalence of MEN1 tumours/lesions in our series with respect to published data* (Continued)
Prevalence in
our patients
n. (%)
Type and combination of tumours/lesions in our patients
n. (%)
Prevalence in published
literature
(%)
Adrenocortical tumours/
lesions
27 (18.62%) 40%
27 total tumours/lesions of adrenal glands:
- 9 hyperplasia (5 monolateral, 4 bilateral) (6.21% of MEN1 affected
patients; 33.33% of adrenal gland tumours/lesions)
- 18 adenomas (15 monolateral, 3 bilateral) (12.41% of MEN1 affected
patients; 66.67% of adrenal gland tumours/lesions)
Other lesions 19 (13.10%) n.a.
20 total other associated tumours:
- 3 meningiomas (2.07% of MEN1 affected patients) 8%
- 4 breast cancers (4.21% of MEN1 affected women) n.a
- 12 uterine lesions (12.63% of MEN1 affected women) n.a
- 1 perineal aggressive angiomixoma (0.69% of MEN1 affected patients) n.a.
Footnotes: N number, PHPT Primary hyperparathyroidism, GEP-NETs gastro-entero-pancreatic neuroendocrine tumours, pNFTs Pancreatic non-functioning tumours,
NF-NET Non-functioning neuroendocrine tumour, VIP Vasoactive intestinal peptide, PP Pancreatic polypeptide, PRLoma Prolactinoma, NFA Non-functioning
adenoma, GH Growth hormone (somatotropin), ACTH adreno-cortico tropic hormone (corticotropin), N.A. non-available
*Thakker et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endcocrinol Metab 97(9): 2990–3011, 2012
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whose PRL over-secretion could not be controlled by
pharmacological therapy.
Principal characteristics and treatments of pituitary
tumours in our series are reported in Table 5.
Carcinoids
Seventeen patients (14 women and 3 men) presented
bronchopulmonary carcinoids (11.72% of MEN1 affected
patients) with a mean age of tumour diagnosis of 47.3+
12.5 years (range 26–73 years). One man showed a
well-differentiated lung carcinoid at the age of 49 years
as the first manifestation of MEN1 (0.69% of MEN1 af-
fected patients); he was clinically and genetically diag-
nosed with MEN1 at the age of 50 after showing a
well-differenced gastric NF-NET and a micro-PRLoma
(interestingly at the age of 59 he had not manifested
PHPT yet).
No thymic carcinoids were described in our series.
Twenty-nine patients underwent surgical ablation of
thymus, at the same time of parathyroid surgery, to pre-
vent the development of thymus carcinoids.
Skin lesions
Forty-four patients (30 women and 14 men) presented
MEN1-typical skin lesions (30.34% of affected patients).
Distribution and combinations of skin lesions is reported
in Table 1. Lipomas (single or multiple) were the most
common skin lesion (37/53) affecting 37 patients (25.52%
of MEN1 affected patients and 69.81% of all skin lesions),
both alone (20 cases) or in combination with other skin
Table 3 Main characteristics and treatments of PHPT in our series of MEN1 patients
PHPT Patients
n. (%)
Clinical presentation Surgery Pharmacological
treatment
(Calcimimetic)
n. (%)
Symptomatic
n. (%)
Asymptomatic
n. (%)
No
surgery
n. (%)
TPT
n. (%)
SPT
n. (%)
PPT
n. (%)
Total patients
with PHPT
139
(95.87%)
54 (37.24%) 85 (58.62%) 40
(28.78%)
47 (33.81%)
- 43 with tissue autograft in
the non-dominant forearm
- 4 without tissue autograft
17
(12.23%)
35
(25.18%)
26 (18.70%)
PHPT as first
clinical
manifestation
92
(63.45%)
43 (29.66%)
- 29 nephrocalcinosis
(20%)
- 7 nephrocalcinosis
and osteoporosis
(4.83%)
- 5 osteoporosis (3.45%)
- 2 nephrocalcinosis
and osteopenia
(1.38%)
49 (33.79%) 23
(16.55%)
29 (20.86%)
- 28 with tissue autograft in
the non-dominant forearm
- 1 without tissue autograft
12
(8.63%)
28
(20.14%)
16 (11.51%)
Index cases
(probands)
85
(58.62%)
37 (25.52%)
- 26 nephrocalcinosis
(17.93%)
- 5 nephrocalcinosis
and osteoporosis
(3.45%)
- 3 osteoporosis (2.07%)
- 2 osteopenia (1.38%)
- 1 nephrocalcinosis
and osteopenia
(0.69%)
48 (33.10%) 19
(13.67%)
33 (23.74%)
- 30 with tissue autograft in
the non-dominant forearm
- 3 without tissue autograft
10
(7.19%)
23
(16.55%)
17 (12.23%)
Relatives 54
(37.24%)
16 (11.03%)
- 9 nephrocalcinosis
(6.21%)
- 4 osteoporosis (2.76%)
- 2 nephrocalcinosis
and osteoporosis
(1.38%)
- 1 nephrocalcinosis
and osteopenia
(0.69%)
38 (26.21%) 21
(15.11%)
14 (10.07%)
- 13 with tissue autograft in
the non-dominant forearm
- 1 without tissue autograft
7
(5.04%)
12
(8.63%)
9 (6.48%)
Footnotes: PHPT Primary hyperparathyroidism, N number, TPT Total parathyroidectomy (all four glands removed), SPT Subtotal parathyroidectomy (three glands
and part of the forth gland removed), PPT Partial parathyroidectomy (three or less glands removed)
Percentages of clinical presentation were calculated with respect to MEN1 clinically affected patients (145). Percentages of surgery and pharmacological treatment
were calculated with respect to PHPT affected patients (139)
Surgical interventions in Table 3 included only the first parathyroid surgery (14 PPTs and 2 SPTs required a second parathyroid intervention for recurrences: 10
TPTs, 2 SPTs and 4 PPTs)
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lesions (7 cases; 5 with angiofibromas, one with angiomas
and one with angiofibromas and fibromas).
Lipomas were the first clinical manifestation of MEN1
in 7 cases (4.83% of affected patients) with a mean age
of onset of 21.9 + 11.5 years (range 9–39 years); 3 were
index cases (mean age 33.7 + 6.2 years; range 25–
39 years) and 4 were relatives (mean age 13.0 + 4.3 years;
range 9–20 years). Mean age of MEN1 diagnosis of these
7 patients was 27.2 + 13.5 years (range 7–39 years);
mean age of MEN1 diagnosis of index cases was
37.7 + 3.4 years (range 33–41 years) while in relatives it
was 16.7 + 11.6 years (range 7–33 years).
Adrenocortical tumours/lesions
Twenty-seven patients (22 women and 5 men) were
affected by tumours/lesions of the adrenal glands
(18.62% of affected patients), as detailed reported in
Table 1.
Mean age of tumour/hyperplasia diagnosis was
47.0 + 12.4 years (range 31–62 years), while mean age at
MEN1 diagnosis was 39.1 + 12.2 years (range 21–
73 years).
Adrenocortical adenoma/hyperplasia never resulted to
be the first MEN1 manifestation in our series of
patients.
Table 4 Main characteristics and treatments of GEP-NETs in our series of MEN1 patients
GEP-NETs Patients
n. (%)
Clinical presentation Surgery Pharmacological treatment
FTs
n. (%)
NFTs
(including
PPoma)
n. (%)
Combination
of FT and
NFT
n. (%)
No
surgery
n. (%)
WP
n. (%)
Enucleation
or PPR
n. (%)
(SSAs)
n. (%)
Radionuclide therapy
with (177)Lu-DOTATA
TE
n. (%)
Total patients with
GEP-NETs
86
(59.31%)
47 (32.41%)
- 28 gastrinomas
alone (19.31%)
- 13 insulinomas
alone (8.97%)
- 2 VIPomas
alone (1.38%)
- 3 gastrinoma-
insulinoma
(2.07%)
- 1 gastrinoma-
glucagonoma
(0.69%)
30 (20.69%)
- 28 pNFTs
(19.31%)
- 1 PPoma
(0.69%)
- 1 pNFT-
gastric NF
NET (0.69%)
9 (6.21%)
- 9
gastrinoma-
PNFTs
(6.21%)
41
(47.67%)
17
(19.77%)
28 (32.56%) 18
(20.93%)
2 (2.36%)
A GEP-NET as first
clinical
manifestation
20
(13.79%)
18 (12.41%)
- 9 gastrinomas
(6.21%)
- 8 insulinomas
(5.52%)
- 1 VIPoma
(0.69%)
2 (1.38%)
- 1 PPoma
(0.69%)
- 1 gastric NF
NET (0.69%)
0 5
(5.81%)
6
(6.98%)
9 (10.47%) 4
(4.65%)
1 (1.16%)
Index cases
(probands)
65
(44.83%)
39 (26.90%)
- 22 gastrinomas
alone (15.17%)
- 11 insulinomas
alone (7.59%)
- 2 VIPomas
alone (1.38%)
- 3 gastrinoma-
insulinoma
(2.07%)
- 1 gastrinoma-
glucagonoma
(0.69%)
17 (11.72%)
- 16 pNFTs
(11.03%)
- 1 pNFT-
gastric NF
NET (0.69%)
9 (6.21%)
- 9
gastrinoma-
PNFTs
(6.21%)
25
(29.07%)
17
(19.77%)
23 (26.74%) 12
(13.95%)
2 (2.36%)
Relatives 21
(14.48%)
8 (5.52%)
- 6 gastrinomas
alone (4.14%)
- 2 insulinomas
alone (1.38%)
13 (8.97%)
- 12 pNFTs
(8.28%)
- 1 PPoma
(0.69%)
0 16
(18.60%)
0 5 (5.81%) 6
(6.98%)
0
Footnotes: N number, FTs Functioning tumours, NFTs Non-functioning tumours, pNFTs pancreatic non-functioning tumours, NET Neuroendocrine tumours, WP
Whipple’s procedure (pancreaticoduodenectomy; removal of the head of the pancreas, the duodenum, the proximal jejunum, gallbladder, and part of the
stomach), PPR Partial pancreas resection (partial pancreatoctomy), SSAs somatostatin analogues (octreotide or lanreotide)
Percentages of clinical presentation were calculated with respect to MEN1 clinically affected patients (145). Percentages of surgery and pharmacological
treatments were calculated with respect to GEP-NET affected patients (86)
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MEN1 mutational analysis
One hundred forty-nine patients (90.3%) resulted to bear
a MEN1 point or an intra-exon small frameshift muta-
tion, within the coding region or the splicing sites of the
gene, identified by PCR-based Sanger’s sequencing.
Seventy-eight of them were index cases (58 familial cases
from 47 pedigrees and 20 single cases), while 71 were
first-degree relatives of a mutation carrier, from 36 pedi-
grees (20 were still asymptomatic at the time of this
study and they were excluded from genotype-phenotype
association analyses).
One family [5] members: 1 index case and four rela-
tives (one still asymptomatic) resulted carriers of two
different inactivating MEN1 mutations, one in exon 4
(Leu249Pro missense mutation) and one in exon 8
(g.1181delC frameshift mutation), both located on the
same MEN1 allele and inherited from the father of the
index case.
Four patients (from two pedigrees) were identified as
carriers of a large intragenic deletion, spanning more than
one entire exon, by MPLA. Two other patients (brother
and sister) resulted carriers of a familial predisposing
haplotype by microsatellite analysis at 11q13 locus [5].
Ten patients (three familial cases from the same pedi-
gree and seven single cases) resulted negative to MEN1
mutation sequencing analysis, and were not further
analysed by other screening techniques; they were all
clinically diagnosed with MEN1.
Genetic test allowed to identify a total of 34 mutations
carriers who were still asymptomatic at the time of
MEN1 genetic diagnosis. Twenty of them were still
asymptomatic at the time of this study. Fourteen [genet-
ically diagnosed at mean age of 20.1 + 9.6 years (range
7–33 years)] developed the first clinical manifestation
(mean age 24.1 + 7.7 years; range 14–34 years), after
genetic diagnosis and during the time of the study.
Table 6 resumes the distribution of mutation types in
our patients. A total of 59 different mutations were de-
scribed, including two different mutations carried by one
family (double mutation) and two large intra-genic dele-
tions spanning more than one exon. Frameshift muta-
tions (22) were the most common (37.93%); one
frameshift mutation was carried by two unrelated pedi-
grees. We identified 17 different missense mutations
(29.31%); three of them were, respectively, carried by: 1)
two families and one single case; 2) two families; 3) two
families. Six different nonsense mutations were reported
(10.34%); two of them were carried by 3 pedigrees and
one single case, and by one family and 2 single cases, re-
spectively. Total identified splicing site mutations were
10 (17.24%); one of them affecting two different unre-
lated pedigrees.
Table 5 Main characteristics and treatments of pituitary tumours in our series of MEN1 patients
Pituitary tumours Patients
n. (%)
Clinical presentation Surgery Pharmacological
treatment
Dopamine
agonist
(Cabergoline)
n. (%)
FTs
n. (%)
NFAs
n. (%)
Combination of FTs
n. (%)
No
surgery
n. (%)
Transphenoidal
resection
n. (%)
Total patients with pituitary
tumours
75
(51.72)%)
62 (42.76%)
- 59 PRLomas
(40.69%)
- 3
corticotropinoma
(2.07%)
12
(8.28%)
1 (0.69%)
- 1 PRLoma-1 somatotropi-
noma (0.69%)
64
(85.33%)
11 (14.67%) 30 (40%)
A pituitary tumour as first
clinical manifestation
25
(17.24%)
25 (17.24%)
- 24 PRLomas
(16.55%)
- 1
corticotropinoma
(0,69%)
0 0 18
(24%)
7 (9.33%) 10 (13.33%)
Index cases (probands) 54
(37.24%)
44 (30.34%)
- 41 PRLomas
(28.28%)
- 3
corticotropinoma
(2.07%)
9
(6.21%)
1 (0.69%)
- 1 PRLoma-1 somatotropi-
noma (0.69%)
44
(58.67%)
10 (13.33%) 17 (22.67%)
Relatives 21
(14.48%)
18 (12.41%)
- 18 PRLomas
(12.41%)
3
(2.07%
0 20
(26.67%)
1 (1.33%) 13 (17.33%)
Footnotes: FTs Functioning tumours, NFAs non-functioning adenomas, PRLoma Prolactinoma
Percentages of clinical presentation were calculated with respect to MEN1 clinically affected patients (145). Percentages of surgery and pharmacological treatment
were calculated with respect to pituitary adenoma affected patients (75)
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Distribution of mutations along the MEN1 exons and
exon-intron junctions is reported in Table 7.
Exons 2, 9 and 10 resulted to be the three most mu-
tated exons, with 9, 10 and 12 different mutations, re-
spectively. Exons 9 and 10, which encodes nuclear
localization signals (NLSs) of menin, are prevalently af-
fected by frameshift and nonsense mutations which cre-
ate a premature STOP codon and a truncated menin
protein missing one or more NLSs and unable to react
the nucleus. Missense mutations in exon 9 (codons 396–
450) are all concentrated between codons 414–444, af-
fecting binding sites of JUND (codons 323–428),
NM23H1 (codons 1–486), RPA2 (codons 286–448),
HDAC1 (codons 145–450) and CHES1 (codons 428–
610). Splicing sites mutations are prevalently located in
introns 4 and 5.
We analysed also the distribution of tumours/
lesions with respect to different mutations, and any
possible correlation between genotype and clinical
phenotype (including in the analyses 129 symptomatic
patients bearing a point or frameshift mutation, 4 pa-
tients carrying a large intra-genic deletion and 2 pa-
tients presenting a familial 11q13 predisposing
haplotype). Table 8 reports tumours distributions with
respect to MEN1 mutation type, while Table 9 with
respect to mutated exon/intron.
Statistical analyses did not evidence any significant dif-
ference neither between disease age of onset and MEN1
four main mutation types or mutation localization, nor
in the distribution of PHPT and pituitary tumours be-
tween different MEN1 mutation types and localization.
Statistical analyses showed a significantly higher per-
centage of GEP-NETs in patients bearing a frameshift
mutation (68.09%) with respect to missense mutations
(43.24%; χ2 = 5.22, p = 0.022); however, not significant
association was found in patients bearing a nonsense mu-
tation (66.67%) versus patients with a missense mutation
(43.24%; χ2 = 2.66, p = 0.103), suggesting that the only one
reported positive association could be only an accidental
statistical association. Indeed, the specific analysis of
intra-familial MEN1 clinical phenotypes, age of onset, and
disease penetrance (in 36 pedigrees for which we collected
more than one affected member) highlighted a high clin-
ical variability and a personal disease presentation even in
the presence of the same mutation, thus, excluding any
possible direct genotype-phenotype correlation.
Discussion
The institution (and continuous updating) of patients’
large specific registries or databases is very useful in the
management of rare diseases, like MEN1. Indeed, the
collection of clinical, biochemical and genetic character-
istics of unselected patients represents a good approach
to increase the knowledge on epidemiological aspects of
the disease, and natural course and prognosis of single
manifestations of the syndrome.
During the last decade, important national MEN1 da-
tabases favoured the study of epidemiological, diagnos-
tic, clinical and therapeutic aspects of MEN1-associated
tumours, such as the DutchMEN1 Study Group
(DMSG), the Groupe d’Etude des Tumeurs Endocrines
(GTE), the multicentre database of the MEN1 Consor-
tium of Japan [6], and the Italian MEN1 database [7].
Here, we reported the results of the analysis of a large
database of Florentine MEN1 patients from the Referral
Centre for Hereditary Endocrine Tumours of the
“Regione Toscana”, comparing our data with the previ-
ously published. The availability of the Referral Centre
allowed the strict interaction of healthcare specialists in
different areas of NETs and, thus, granted the collection
of extensive data and a continuous long-term follow-up
of patients, as well as the possibility to perform genetic
test and to associate genetic and clinical data.
Table 6 Distribution of MEN1 mutation types in our MEN1 patients
Mutation type Number of different mutations (number of
mutations carried by more than one family/case)
Number of
pedigrees (total
cases)
Number of
single cases
Total number
of patients
Frameshift mutations 22 (1) 17 (46) 6 52
Missense mutations 17 (3) 15 (36) 6 42
Nonsense mutations 6 (2) 7 (18) 4 22
Splicing site mutations 10 (1) 7 (24) 4 28
Double mutation (frameshift and missense) 1 1 (5) 0 5
Large intra-genic deletions 2 2 (4) 0 4
Predisposing familial 11q13 haplotype n.a. 1 (2) 0 2
Patients without an identified MEN1 mutation
(negative Sanger’s sequencing analysis)
n.a. 1 (3) 7 10
Total 58 52 (138) 27 165
Footnote: N.A. Non-applicable
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Given the autosomal dominant partner of inheritance,
MEN1 syndrome manifests an equal gender distribution,
however, in our database a greater predominance (64.2%
vs. 35.8%) of female patients was detected, confirming
what had been previously shown in similar studies carried
out in France, the Netherlands, Japan and Italy [6–9].
The analysis of our MEN1 database confirmed PHPT
as the most common manifestation of the syndrome,
reaching a penetrance of over 95% after the age of 55,
followed by GEP-NETs (about 60%) and pituitary tu-
mours (about 52%), respectively. These data were in ac-
cordance with those previously reported by the Japan
database [6], and found in the Italian MEN1 database
[7], which includes also part of our Florentine patients.
Distribution of GEP-NETs in our database was in ac-
cordance with previously published data [1] for all
tumour types; insulinoma resulted to be higher in Japa-
nese patients (22%) with respect to Western countries
(10%) [1] and our study (about 11%).
Regarding pituitary tumours, our patients showed a higher
prevalence of PRLoma (over 41%) with respect to data re-
ported in the MEN1 International guideline (20%) [1], in the
DMSG database (16%) [8] and in the GTE cohort (30%) [10].
In our cohort PHPT was prevalently treated by TPT
with parathyroid tissue autograft, conversely to a cohort
study of the DMSG in which STP with bilateral
trans-cervical thymectomy was the procedure of choice
[11], and PHPT patients from the MEN1 Japan database
Table 7 Distribution of mutations along coding region and splicing sites of the MEN1 gene
Exon/
intron
Number of different mutations (number of
mutations carried by more than one family/
case)
Number of
pedigrees (total
cases)
Number of
single cases
Total
number of
patients
Type of mutation (number of different
mutations; total number of patients)
Exon 2 9 (1) 7 (19) 3 22 Frameshift (5; 15)
Missense (3; 5)
Splicing site (1; 2)
Intron 2 1 0 1 1 Splicing site (1; 1)
Exon 3 6 (0) 4 (10) 2 12 Frameshift (2; 2)
Missense (4; 10)
Intron 3 1 0 1 1 Splicing site (1; 1)
Exon 4 2 (1) 3 (4) 0 4 Missense (2; 4)
Intron 4 2 (1) 4 (18) 0 18 Splicing site (2; 18)
Exon 5 1 1 (3) 0 3 Frameshift (1; 3)
Intron 5 3 (0) 1 (2) 2 4 Splicing site (3; 4)
Exon 6 2 (0) 2 (5) 0 5 Frameshift (1; 2)
Missense (1; 3)
Intron 6 0 0 0 0 n.a.
Exon 7 1 0 1 1 Frameshift (1; 1)
Intron 7 1 1 (2) 0 2 Splicing site (1; 2)
Exon 8 3 (0) 2 (8) 1 9 Frameshift (2; 5)
Missense (1; 4)
Intron 8 0 0 0 0 n.a.
Exon 9 10 (3) 11 (30) 5 35 Frameshift (3; 8)
Nonsense (2; 12)
Missense (5; 15)
Intron 9 0 0 0 0 n.a.
Exon 10 12 (1) 10 (23) 4 27 Frameshift (7; 16)
Nonsense (4;10)
Missense (1; 1)
Double
mutation
2 (0) 1 (5) 0 5 Frameshift exon 8
Missense exon 4
Total 56 (7) 47 (129) 20 149 Frameshift (23; 57*§)
Nonsense (6; 22#)
Missense (18; 47*¥)
Splicing site (9; 28ɸ)
Footnote: Only point and intra-exon small frameshift mutations were included in this table. Intron mutations are all splicing site mutations and they are all located
near the intron-exon junction affecting splicing regulatory sequences. N.A. non-applicable. * Both these numbers include five individuals bearing two different
mutations on the same MEN1 allele. §This number includes five still asymptomatic carriers. #This number includes four still asymptomatic carriers. ¥This number
includes five still asymptomatic carriers. ɸ This number includes four still asymptomatic carriers
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Table 8 Distribution of MEN1-related tumours/lesions with respect to MEN1 type of mutations
Tumour/lesion (n.) FS
n. (%)
MS
n. (%)
NS
n. (%)
SP
n. (%)
FS +
MS
n. (%)
Intragenic large
deletions
11q13 familial
haplotype
No identified MEN1
mutation*
PHPT (139) 47
(100%)
37
(100%)
17
(94.44%)
22
(91.67%)
3
(75%)
4 (100%) 2 (100%) 7 (70%)
Symptomatic (54) 12
(25.53%)
18
(48.65%)
8
(44.44%)
9
(37.50%)
1
(25%)
3 (75%) 1 (50%) 2 (20%)
Asymptomatic (85) 35
(74.47%)
19
(51.35%)
9 (50%) 13
(54.17%)
2
(50%)
1 (25%) 1 (50%) 5 (50%)
GEP-NETs (86) 32
(68.09%)
16
(43.24%)
12
(66.67%)
13
(54.17%)
2
(50%)
4 (100%) 2 (100%) 5 (50%)
pNFTs (28) 12
(25.53%)
6
(16.22%)
3
(16.67%)
4
(16.67%)
1
(25%)
1 (25%) 0 1 (10%)
PPoma (1) 0 1
(2.70%)
0 0 0 0 0 0
pNFT-gastric NF NET (1) 0 0 0 1
(4.17%)
0 0 0 0
Gastrinomas (28) 7
(14.89%)
3
(8.11%)
5
(27.78%)
7
(29.17%)
1
(25%)
2 (50%) 0 3 (30%)
Insulinomas (13) 6
(12.77%)
2
(5.41%)
3
(16.67%)
1
(4.17%)
0 0 0 1 (10%)
VIPomas (2) 1
(2.13%)
1
(2.70%)
0 0 0 0 0 0
Gastrinoma-insulinoma (3) 2
(4.26%)
1
(2.70%)
0 0 0 0 0 0
Gastrinoma-glucagonoma (1) 0 1
(2.70%)
0 0 0 0 0 0
pNFTs-gastrinoma (9) 4
(8.51%)
1
(2.70%)
1
(5.56%)
0 0 1 (25%) 2 (100%) 0
Pituitary adenomas (75) 24
(51.06%)
19
(51.35%)
10
(55.56%)
11
(45.83%)
3
(75%)
1 (25%) 1 (50%) 6 (60%)
NFAs (12) 4
(8.51%)
2
(5.41%)
3
(16.67%)
2
(8.33%)
0 0 0 1 (10%)
PRLomas (59) 18
(38.30%)
17
(45.95%)
6
(33.33%)
9
(24.32%)
3
(75%)
1 (25%) 1 (50%) 4 (40%)
Corticotropinomas (3) 1
(2.13%)
0 1
(5.56%)
0 0 0 0 1 (10%)
PRLoma-somatotropinoma
(1)
1
(2.13%)
0 0 0 0 0 0 0
Bronchopulmonary carcinoids
(17)
5
(10.64%)
3
(8.11%)
2
(11.11%)
6 (25%) 0 0 0 1 (10%)
Skin lesions
Lipomas (37) 16
(34.04%)
5
(13.51%)
2
(11.11%)
7
(29.17%)
3
(75%)
3 (75%) 0 1 (10%)
Angiomas/angiofibromas/
fibromas (13)
3
(6.38%)
5
(13.51%)
2
(11.11%)
1
(4.17%)
1
(25%)
1 (25%) 0 0
Adrenal gland tumours/lesions
(27)
9
(19.15%)
8
(21.62%)
3
(16.67%)
3
(12.5%)
2
(50%)
1 (25%) 0 1 (10%)
Footnotes: N. number, FS Frameshift, MS Missense, NS nonsense, SP Splicing site, PHPT Primary hyperparathyroidism, GEP-NETs Gastro-entero-pancreatic
neuroendocrine tumours, pNFTs Pancreatic non-functioning tumours, NF NET Non-functioning neuroendocrine tumours, VIP Vasoactive intestinal peptide, NFAs
Non-functioning adenomas
Percentages were calculated with respect to the number of any mutation type in symptomatic patients (47 frameshifts, 18 nonsense, 37 missense, 24 splicing site,
4 double mutation, 4 large intragenic deletions and 2 11q13 predisposing familial haplotype)
*Patients analysed only by PCR-based Sanger’s sequencing
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which were operated, more than a half, by single gland
parathyroidectomy [6]. TPT granted a lower rate of per-
sistence and a longer PHPT-free post-operatory period,
than SPT and PPT. A very low percentage of operated
patients (5.1%) manifest post-surgical permanent hypo-
parathyroidism that has been pharmacologically miti-
gated over the years.
General mean age of diagnosis of the three main clin-
ical MEN1 manifestation in our patients was about
15 years (reaching up to 20 years in case of gastrinomas)
earlier than sporadic counterparts; due to natural char-
acteristics of MEN1 but also favoured by the periodic
tumour-surveillance screening program and constant
follow-up of all MEN1 affected patients and mutation
carriers. MEN1-associated tumours have an earlier age
of onset, with respect to sporadic counterparts, and
often they present a more aggressive course and behav-
iour; an early diagnosis, followed by an early surgical
and/or pharmacological intervention, is the gold stand-
ard for reducing morbidity and mortality. In this light,
the institution of patients’ database helps in better set-
ting and programming a continuous monitoring and
follow-up of patients and periodical screenings of both
affected and asymptomatic mutation carriers, increasing
the reduction of morbidity and mortality of MEN1. Mor-
bidity in our patients was principally due to a hormone
over-secretion (i.e gastrin leading to ZES and causing ul-
cers and bleeding; PRL responsible for amenorrhea, oli-
gomenorrhea and/or galactorrhea in women and
impotence, infertility, decreased libido in men; insulin
provoking hypoglycemia, etc), while mortality was
caused, prevalently, by malignant progression and me-
tastases of not early detected gastrinomas and carci-
noids. Data from the DMSG evidenced that half of
patients, diagnosed with liver metastases from duodeno-
pancreatic NETs, died precociously, in a median
follow-up of 4 years since tumour discovery, prompting
the importance of an early diagnosis and a constant peri-
odic clinical surveillance [12]. Indeed, data from our
database highlighted that all the precociously deceased
patients were characterised by a late diagnosis of MEN1
(about 15 years after the occurrence of the first clinical
manifestation), and they were already presenting, at the
time of diagnosis, malignancies (with or without metas-
tasis) and/or severe tumour-related consequences un-
treatable by current available surgical and/or medical
options. Long-term unrecognised and untreated gastri-
nomas and MEN1-related malignancies were the most
common causes of death among our patients, confirm-
ing data from a GTE study which indicated duodeno-
pancreatic and thymic NETs as responsible for increased
risk of death in MEN1 patients [13].
Data from our database confirmed that biochemical
screenings for hormone over-production are able to
anticipate the diagnosis of MEN1 of over 10 years with
respect to imaging methods, for functioning tumours;
radiological screenings are the only effective diagnostic
method for NF-NETs. Given the high malignant
potential of pancreatic NFTs and their frequency in
MEN1 patients, routine radiological surveillance of
entero-pancreatic tract is mandatory. Our screening
protocol consists in performing abdominal RMI of CT
scan every 3 years in mutation carriers and in MEN1 af-
fected individuals by the age of 20, associated with an
intermediate pancreatic eco-endoscopy at 18 months, or,
alternatively, an abdominal RMI of CT scan every 2 years
without the pancreatic eco-endoscopy. In our series of
patients, these imaging approaches granted the early rec-
ognition of 39 NF pancreatic NETs and a gastric
NF-NET, and the pre-operatory localization of tumours.
None of our patients died for an undiscovered
NF-GEP-NETs, confirming the importance of these ap-
plied diagnostic procedures, accordingly also with sug-
gestion of the GTE group [14].
The genetic test is the only one that grants a real early
diagnosis, allowing the identification of mutation carriers,
within mutated pedigrees, at their still asymptomatic level,
and decades before the appearance of any biochemical
valuable alteration. The application of genetic test in our
patients allowed, indeed, the identification of 34 asymp-
tomatic mutation carriers, 14 of them manifested their
first clinical manifestation of MEN1 a mean of about
4 years after the genetic diagnosis; the constant diagnostic
screening after genetic test granted the early recognition
of the clinical manifestations and favoured a very early
therapeutic intervention. In the last two decades, thanks
to early genetic diagnosis and identification of mutation
carriers at a very young age it has been possible to analyse
MEN1 features and manifestations also in young individ-
uals. For years, evidence and data of MEN1 in childhood
and adolescents had been derived mainly from case re-
ports. Recently, thanks to the establishment of national
databases and collection of large series of patients, two
studies, one from the GTE database [15] and one from
this Florentine database [16], have investigated clinical,
therapeutic and genetic aspects of MEN1 in children and
adolescents (respectively before the age of 21 and 20 years),
favouring the collection of important data regarding the
management of this syndrome in young individuals.
The progressive application ofMEN1 genetic test world-
wide notably decreased MEN1-associated morbidity and
mortality. Unfortunately, MEN1 syndrome shows no dir-
ect correlation between genotype and phenotype [17, 18].
Only one study [19] on the GTE cohort showed that sur-
vival rate of mutated MEN1 patients was significantly
lower among carriers of a MEN1 mutation affecting bind-
ing sites with JunD, presenting a 2-fold higher death risk
of MEN1-associated tumours; no association was found
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between mutations and other peculiar phenotypic fea-
tures. The analysis of our MEN1 patients’ database, as well
as that of the Italian MEN1 database [18], confirmed the
lack of a direct correlation between a specific mutation,
mutation type or mutated gene region with clinical mani-
festations and MEN1 phenotypes, not allowing the setting
of personalised screening and therapeutic programs. The
detailed intra-familial analysis of clinical phenotype, age of
tumour onset, multiple tumour association, disease pene-
trance, severity, course and prognosis in all our pedigrees
with more than one affected member confirmed the total
absence of correlation between these characteristics and
theMEN1 mutation. Only a single positive association be-
tween development of a GEP-NET and frameshift muta-
tions was reported, with respect to missense mutations.
However, this association was not replicated for another
mutation type with similar gap in percentage of tumour
occurrence; this suggested that the positive association
could be only an accidental statistical association. This
datum needs to be verified or denied by further studies in
broad and different MEN1 series of patients. The GTE re-
search group demonstrated, in MEN1 pedigrees from its
database, an intra-familial heritability for pituitary (64%),
adrenal (65%) and thymic NETs (97%), progressively de-
creasing along parental degree distance [20]. The progres-
sive decrease along generations of intra-familial clinical
hereditability and, mostly of all, the absence of direct
genotype-phenotype correlation prompt the hypothesis of
an important, direct role of other modifying factors in the
determination of individual MEN1 tumorigenesis. Since
differences in MEN1 phenotype have been reported also
in identical twins, epigenetics factors, such as microRNAs
and histone modifications, are, currently, considered as
the most probable responsible determinants, presumably
triggered by environmental factors, to define the MEN1
phenotype in patients bearing the same MEN1 mutation.
Identification and study of these factors, thanks to the
availability of patients’ databases and tissue banks, are
mandatory for a complete comprehension of MEN1
tumorigenesis, and for the development of new target
diagnostic and therapeutic strategies.
Conclusions
In conclusion, our long-term clinical practice (as Refer-
ral Centre for endocrine inherited tumour syndromes),
together with the institution of an over 25 year-lasting
MEN1 patients’ database, highlighted that the collection
of data (including a detailed family and personal clinical
and therapeutic history), the performance of the genetic
test in patients and first-degree relatives, as well as the
continuous follow up are essential for a correct and early
diagnosis and for granting patients the best available
diagnostic and therapeutic management.
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